Androgen deprivation therapy prevents bladder cancer recurrence
Although accumulating preclinical evidence indicates the involvement of androgen receptor signals in bladder cancer (BC) development, its clinical relevance remains unclear. We aimed to evaluate the predictive role of androgen deprivation therapy (ADT) in BC recurrence in prostate cancer (PC) patien...
Gespeichert in:
| Veröffentlicht in: | Oncotarget 2014-12, Vol.5 (24), p.12665-12674 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12674 |
|---|---|
| container_issue | 24 |
| container_start_page | 12665 |
| container_title | Oncotarget |
| container_volume | 5 |
| creator | Izumi, Koji Taguri, Masataka Miyamoto, Hiroshi Hara, Yoshinori Kishida, Takeshi Chiba, Kimio Murai, Tetsuo Hirai, Kotaro Suzuki, Kotaro Fujinami, Kiyoshi Ueki, Teiichiro Udagawa, Koichi Kitami, Kazuo Moriyama, Masatoshi Miyoshi, Yasuhide Tsuchiya, Futoshi Ikeda, Ichiro Kobayashi, Kazuki Sato, Maho Morita, Satoshi Noguchi, Kazumi Uemura, Hiroji |
| description | Although accumulating preclinical evidence indicates the involvement of androgen receptor signals in bladder cancer (BC) development, its clinical relevance remains unclear. We aimed to evaluate the predictive role of androgen deprivation therapy (ADT) in BC recurrence in prostate cancer (PC) patients. We retrospectively reviewed 20,328 patients with PC diagnosed during 1991-2013 and identified 239 (1.2%) men having primary BC. After excluding ineligible patients, 162 patients made up a final cohort. With a median follow-up of 62 months, 38 (50%) of 76 control patients without ADT experienced BC recurrence, while 19 (22%) of 86 did in ADT group. Thus, patients having received ADT for their PC showed a significantly lower risk of BC recurrence (5-year actuarial recurrence-free survival: 76% v 40%; P < 0.001) and also had a significantly smaller number of recurrence episodes (5-year cumulative recurrence: 0.44 v 1.54; P < 0.001), compared to the control patients. A multivariable analysis revealed ADT as an independent prognosticator (hazard ratio, 0.29; 95% confidence interval, 0.17-0.49) for BC recurrence. This is the first clinical study showing that ADT significantly reduces the risk of BC recurrence. |
| doi_str_mv | 10.18632/oncotarget.2851 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4350350</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1652402022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-9a4240545752b14661a0ad1f4f267ba4e27eb67931cbceace3f3bfd38a139c5f3</originalsourceid><addsrcrecordid>eNpVUEtLw0AQXkSxpfbuSXL0kpp95XFRSvEFBS96XiabSRtJd-NuWui_d2trrcPAfMzr-_gIuabJhOYpZ3fWaNuDW2A_YbmkZ2RIC1HETEp-foIHZOz9ZxJCiixnxSUZhLbMWJoPycPUVM4u0EQVdq7ZQN9YE_VLdNBto87hBk3vo7KFqkIXaTA6FId67RwGfEUuamg9jg91RD6eHt9nL_H87fl1Np3HmkvRxwUIJgK_zCQrqUhTCglUtBY1S7MSBLIMyzQrONWlRtDIa17WFc-B8kLLmo_I_f5vty5XWOmgykGrguQVuK2y0Kj_E9Ms1cJulOAy2eWI3B4eOPu1Rt-rVeM1ti0YtGuvaCqDQpYwFlaT_ap21nuH9ZGGJurHevVnvdpZH05uTuUdD36N5t_6w4Qi</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1652402022</pqid></control><display><type>article</type><title>Androgen deprivation therapy prevents bladder cancer recurrence</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Izumi, Koji ; Taguri, Masataka ; Miyamoto, Hiroshi ; Hara, Yoshinori ; Kishida, Takeshi ; Chiba, Kimio ; Murai, Tetsuo ; Hirai, Kotaro ; Suzuki, Kotaro ; Fujinami, Kiyoshi ; Ueki, Teiichiro ; Udagawa, Koichi ; Kitami, Kazuo ; Moriyama, Masatoshi ; Miyoshi, Yasuhide ; Tsuchiya, Futoshi ; Ikeda, Ichiro ; Kobayashi, Kazuki ; Sato, Maho ; Morita, Satoshi ; Noguchi, Kazumi ; Uemura, Hiroji</creator><creatorcontrib>Izumi, Koji ; Taguri, Masataka ; Miyamoto, Hiroshi ; Hara, Yoshinori ; Kishida, Takeshi ; Chiba, Kimio ; Murai, Tetsuo ; Hirai, Kotaro ; Suzuki, Kotaro ; Fujinami, Kiyoshi ; Ueki, Teiichiro ; Udagawa, Koichi ; Kitami, Kazuo ; Moriyama, Masatoshi ; Miyoshi, Yasuhide ; Tsuchiya, Futoshi ; Ikeda, Ichiro ; Kobayashi, Kazuki ; Sato, Maho ; Morita, Satoshi ; Noguchi, Kazumi ; Uemura, Hiroji</creatorcontrib><description>Although accumulating preclinical evidence indicates the involvement of androgen receptor signals in bladder cancer (BC) development, its clinical relevance remains unclear. We aimed to evaluate the predictive role of androgen deprivation therapy (ADT) in BC recurrence in prostate cancer (PC) patients. We retrospectively reviewed 20,328 patients with PC diagnosed during 1991-2013 and identified 239 (1.2%) men having primary BC. After excluding ineligible patients, 162 patients made up a final cohort. With a median follow-up of 62 months, 38 (50%) of 76 control patients without ADT experienced BC recurrence, while 19 (22%) of 86 did in ADT group. Thus, patients having received ADT for their PC showed a significantly lower risk of BC recurrence (5-year actuarial recurrence-free survival: 76% v 40%; P < 0.001) and also had a significantly smaller number of recurrence episodes (5-year cumulative recurrence: 0.44 v 1.54; P < 0.001), compared to the control patients. A multivariable analysis revealed ADT as an independent prognosticator (hazard ratio, 0.29; 95% confidence interval, 0.17-0.49) for BC recurrence. This is the first clinical study showing that ADT significantly reduces the risk of BC recurrence.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.2851</identifier><identifier>PMID: 25557268</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Aged ; Aged, 80 and over ; Androgens - deficiency ; Androgens - metabolism ; Cohort Studies ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local - prevention & control ; Research Paper ; Retrospective Studies ; Urinary Bladder Neoplasms - drug therapy ; Urinary Bladder Neoplasms - therapy</subject><ispartof>Oncotarget, 2014-12, Vol.5 (24), p.12665-12674</ispartof><rights>Copyright: © 2014 Izumi et al. 2014</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-9a4240545752b14661a0ad1f4f267ba4e27eb67931cbceace3f3bfd38a139c5f3</citedby><cites>FETCH-LOGICAL-c354t-9a4240545752b14661a0ad1f4f267ba4e27eb67931cbceace3f3bfd38a139c5f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350350/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350350/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25557268$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Izumi, Koji</creatorcontrib><creatorcontrib>Taguri, Masataka</creatorcontrib><creatorcontrib>Miyamoto, Hiroshi</creatorcontrib><creatorcontrib>Hara, Yoshinori</creatorcontrib><creatorcontrib>Kishida, Takeshi</creatorcontrib><creatorcontrib>Chiba, Kimio</creatorcontrib><creatorcontrib>Murai, Tetsuo</creatorcontrib><creatorcontrib>Hirai, Kotaro</creatorcontrib><creatorcontrib>Suzuki, Kotaro</creatorcontrib><creatorcontrib>Fujinami, Kiyoshi</creatorcontrib><creatorcontrib>Ueki, Teiichiro</creatorcontrib><creatorcontrib>Udagawa, Koichi</creatorcontrib><creatorcontrib>Kitami, Kazuo</creatorcontrib><creatorcontrib>Moriyama, Masatoshi</creatorcontrib><creatorcontrib>Miyoshi, Yasuhide</creatorcontrib><creatorcontrib>Tsuchiya, Futoshi</creatorcontrib><creatorcontrib>Ikeda, Ichiro</creatorcontrib><creatorcontrib>Kobayashi, Kazuki</creatorcontrib><creatorcontrib>Sato, Maho</creatorcontrib><creatorcontrib>Morita, Satoshi</creatorcontrib><creatorcontrib>Noguchi, Kazumi</creatorcontrib><creatorcontrib>Uemura, Hiroji</creatorcontrib><title>Androgen deprivation therapy prevents bladder cancer recurrence</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>Although accumulating preclinical evidence indicates the involvement of androgen receptor signals in bladder cancer (BC) development, its clinical relevance remains unclear. We aimed to evaluate the predictive role of androgen deprivation therapy (ADT) in BC recurrence in prostate cancer (PC) patients. We retrospectively reviewed 20,328 patients with PC diagnosed during 1991-2013 and identified 239 (1.2%) men having primary BC. After excluding ineligible patients, 162 patients made up a final cohort. With a median follow-up of 62 months, 38 (50%) of 76 control patients without ADT experienced BC recurrence, while 19 (22%) of 86 did in ADT group. Thus, patients having received ADT for their PC showed a significantly lower risk of BC recurrence (5-year actuarial recurrence-free survival: 76% v 40%; P < 0.001) and also had a significantly smaller number of recurrence episodes (5-year cumulative recurrence: 0.44 v 1.54; P < 0.001), compared to the control patients. A multivariable analysis revealed ADT as an independent prognosticator (hazard ratio, 0.29; 95% confidence interval, 0.17-0.49) for BC recurrence. This is the first clinical study showing that ADT significantly reduces the risk of BC recurrence.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Androgens - deficiency</subject><subject>Androgens - metabolism</subject><subject>Cohort Studies</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - prevention & control</subject><subject>Research Paper</subject><subject>Retrospective Studies</subject><subject>Urinary Bladder Neoplasms - drug therapy</subject><subject>Urinary Bladder Neoplasms - therapy</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUEtLw0AQXkSxpfbuSXL0kpp95XFRSvEFBS96XiabSRtJd-NuWui_d2trrcPAfMzr-_gIuabJhOYpZ3fWaNuDW2A_YbmkZ2RIC1HETEp-foIHZOz9ZxJCiixnxSUZhLbMWJoPycPUVM4u0EQVdq7ZQN9YE_VLdNBto87hBk3vo7KFqkIXaTA6FId67RwGfEUuamg9jg91RD6eHt9nL_H87fl1Np3HmkvRxwUIJgK_zCQrqUhTCglUtBY1S7MSBLIMyzQrONWlRtDIa17WFc-B8kLLmo_I_f5vty5XWOmgykGrguQVuK2y0Kj_E9Ms1cJulOAy2eWI3B4eOPu1Rt-rVeM1ti0YtGuvaCqDQpYwFlaT_ap21nuH9ZGGJurHevVnvdpZH05uTuUdD36N5t_6w4Qi</recordid><startdate>20141230</startdate><enddate>20141230</enddate><creator>Izumi, Koji</creator><creator>Taguri, Masataka</creator><creator>Miyamoto, Hiroshi</creator><creator>Hara, Yoshinori</creator><creator>Kishida, Takeshi</creator><creator>Chiba, Kimio</creator><creator>Murai, Tetsuo</creator><creator>Hirai, Kotaro</creator><creator>Suzuki, Kotaro</creator><creator>Fujinami, Kiyoshi</creator><creator>Ueki, Teiichiro</creator><creator>Udagawa, Koichi</creator><creator>Kitami, Kazuo</creator><creator>Moriyama, Masatoshi</creator><creator>Miyoshi, Yasuhide</creator><creator>Tsuchiya, Futoshi</creator><creator>Ikeda, Ichiro</creator><creator>Kobayashi, Kazuki</creator><creator>Sato, Maho</creator><creator>Morita, Satoshi</creator><creator>Noguchi, Kazumi</creator><creator>Uemura, Hiroji</creator><general>Impact Journals LLC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20141230</creationdate><title>Androgen deprivation therapy prevents bladder cancer recurrence</title><author>Izumi, Koji ; Taguri, Masataka ; Miyamoto, Hiroshi ; Hara, Yoshinori ; Kishida, Takeshi ; Chiba, Kimio ; Murai, Tetsuo ; Hirai, Kotaro ; Suzuki, Kotaro ; Fujinami, Kiyoshi ; Ueki, Teiichiro ; Udagawa, Koichi ; Kitami, Kazuo ; Moriyama, Masatoshi ; Miyoshi, Yasuhide ; Tsuchiya, Futoshi ; Ikeda, Ichiro ; Kobayashi, Kazuki ; Sato, Maho ; Morita, Satoshi ; Noguchi, Kazumi ; Uemura, Hiroji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-9a4240545752b14661a0ad1f4f267ba4e27eb67931cbceace3f3bfd38a139c5f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Androgens - deficiency</topic><topic>Androgens - metabolism</topic><topic>Cohort Studies</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - prevention & control</topic><topic>Research Paper</topic><topic>Retrospective Studies</topic><topic>Urinary Bladder Neoplasms - drug therapy</topic><topic>Urinary Bladder Neoplasms - therapy</topic><toplevel>online_resources</toplevel><creatorcontrib>Izumi, Koji</creatorcontrib><creatorcontrib>Taguri, Masataka</creatorcontrib><creatorcontrib>Miyamoto, Hiroshi</creatorcontrib><creatorcontrib>Hara, Yoshinori</creatorcontrib><creatorcontrib>Kishida, Takeshi</creatorcontrib><creatorcontrib>Chiba, Kimio</creatorcontrib><creatorcontrib>Murai, Tetsuo</creatorcontrib><creatorcontrib>Hirai, Kotaro</creatorcontrib><creatorcontrib>Suzuki, Kotaro</creatorcontrib><creatorcontrib>Fujinami, Kiyoshi</creatorcontrib><creatorcontrib>Ueki, Teiichiro</creatorcontrib><creatorcontrib>Udagawa, Koichi</creatorcontrib><creatorcontrib>Kitami, Kazuo</creatorcontrib><creatorcontrib>Moriyama, Masatoshi</creatorcontrib><creatorcontrib>Miyoshi, Yasuhide</creatorcontrib><creatorcontrib>Tsuchiya, Futoshi</creatorcontrib><creatorcontrib>Ikeda, Ichiro</creatorcontrib><creatorcontrib>Kobayashi, Kazuki</creatorcontrib><creatorcontrib>Sato, Maho</creatorcontrib><creatorcontrib>Morita, Satoshi</creatorcontrib><creatorcontrib>Noguchi, Kazumi</creatorcontrib><creatorcontrib>Uemura, Hiroji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Izumi, Koji</au><au>Taguri, Masataka</au><au>Miyamoto, Hiroshi</au><au>Hara, Yoshinori</au><au>Kishida, Takeshi</au><au>Chiba, Kimio</au><au>Murai, Tetsuo</au><au>Hirai, Kotaro</au><au>Suzuki, Kotaro</au><au>Fujinami, Kiyoshi</au><au>Ueki, Teiichiro</au><au>Udagawa, Koichi</au><au>Kitami, Kazuo</au><au>Moriyama, Masatoshi</au><au>Miyoshi, Yasuhide</au><au>Tsuchiya, Futoshi</au><au>Ikeda, Ichiro</au><au>Kobayashi, Kazuki</au><au>Sato, Maho</au><au>Morita, Satoshi</au><au>Noguchi, Kazumi</au><au>Uemura, Hiroji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Androgen deprivation therapy prevents bladder cancer recurrence</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2014-12-30</date><risdate>2014</risdate><volume>5</volume><issue>24</issue><spage>12665</spage><epage>12674</epage><pages>12665-12674</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>Although accumulating preclinical evidence indicates the involvement of androgen receptor signals in bladder cancer (BC) development, its clinical relevance remains unclear. We aimed to evaluate the predictive role of androgen deprivation therapy (ADT) in BC recurrence in prostate cancer (PC) patients. We retrospectively reviewed 20,328 patients with PC diagnosed during 1991-2013 and identified 239 (1.2%) men having primary BC. After excluding ineligible patients, 162 patients made up a final cohort. With a median follow-up of 62 months, 38 (50%) of 76 control patients without ADT experienced BC recurrence, while 19 (22%) of 86 did in ADT group. Thus, patients having received ADT for their PC showed a significantly lower risk of BC recurrence (5-year actuarial recurrence-free survival: 76% v 40%; P < 0.001) and also had a significantly smaller number of recurrence episodes (5-year cumulative recurrence: 0.44 v 1.54; P < 0.001), compared to the control patients. A multivariable analysis revealed ADT as an independent prognosticator (hazard ratio, 0.29; 95% confidence interval, 0.17-0.49) for BC recurrence. This is the first clinical study showing that ADT significantly reduces the risk of BC recurrence.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>25557268</pmid><doi>10.18632/oncotarget.2851</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1949-2553 |
| ispartof | Oncotarget, 2014-12, Vol.5 (24), p.12665-12674 |
| issn | 1949-2553 1949-2553 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4350350 |
| source | MEDLINE; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free E- Journals |
| subjects | Aged Aged, 80 and over Androgens - deficiency Androgens - metabolism Cohort Studies Disease-Free Survival Female Humans Male Middle Aged Neoplasm Recurrence, Local - prevention & control Research Paper Retrospective Studies Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - therapy |
| title | Androgen deprivation therapy prevents bladder cancer recurrence |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T21%3A57%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Androgen%20deprivation%20therapy%20prevents%20bladder%20cancer%20recurrence&rft.jtitle=Oncotarget&rft.au=Izumi,%20Koji&rft.date=2014-12-30&rft.volume=5&rft.issue=24&rft.spage=12665&rft.epage=12674&rft.pages=12665-12674&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.2851&rft_dat=%3Cproquest_pubme%3E1652402022%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1652402022&rft_id=info:pmid/25557268&rfr_iscdi=true |